Please wait while the transcript is being prepared...
0:00
This talk introduces
monotherapy versus
combination therapy
using it as a basis for
further exploration
of monotherapy
and combination therapy,
their definitions,
applications, and
roles in treating a
range of diseases,
such as infections, cancer
and chronic conditions.
We will examine the benefits
and limitations
of each approach,
including resistance, efficacy,
toxicity, and patient adherence.
Evidence from clinical
trials will be
highlighted to guide when
each strategy is appropriate.
Finally, we will emphasize
the importance of
individualized evidence
based decision
making to optimize
therapeutic outcomes.
This lecture
explores monotherapy
and combination therapy,
key concepts in
medical therapeutics.
Monotherapy uses a single
agent to manage a disorder,
whereas combination
therapy employs
two or more agents with
distinct mechanisms.
Both have broad applications
from infectious diseases like
tuberculosis and HIV to
chronic illnesses
such as hypertension,
diabetes, cancer, and
auto immune disease.
Understanding the
strengths, limitations,
and best uses of
these approaches
is crucial for
optimizing outcomes,
minimizing toxicity,
and managing costs.
Monotherapy is often favored as
the initial approach
due to its simplicity.
Using a single agent can
reduce side effects,
drug interactions, and
treatment complexity
which may improve adherence.
It may be sufficient for
mild or stable disease
or when a highly effective
agent is available,
allowing for clear
identification of
